Amylyx Pharmaceuticals (AMLX) Net Margin (2021 - 2024)
Historic Net Margin for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q4 2024 value amounting to 141.71%.
- Amylyx Pharmaceuticals' Net Margin fell 1452700.0% to 141.71% in Q4 2024 from the same period last year, while for Sep 2025 it was 567.71%, marking a year-over-year decrease of 4478700.0%. This contributed to the annual value of 263.74% for FY2024, which is 2751100.0% down from last year.
- As of Q4 2024, Amylyx Pharmaceuticals' Net Margin stood at 141.71%, which was down 1452700.0% from 17476.92% recorded in Q3 2024.
- Amylyx Pharmaceuticals' 5-year Net Margin high stood at 20.36% for Q2 2023, and its period low was 17476.92% during Q3 2024.
- Moreover, its 4-year median value for Net Margin was 141.71% (2024), whereas its average is 3902.46%.
- Its Net Margin has fluctuated over the past 5 years, first skyrocketed by 98461000bps in 2023, then crashed by -174956000bps in 2024.
- Quarter analysis of 4 years shows Amylyx Pharmaceuticals' Net Margin stood at 8120.0% in 2021, then soared by 98bps to 164.94% in 2022, then skyrocketed by 102bps to 3.56% in 2023, then crashed by -4081bps to 141.71% in 2024.
- Its Net Margin was 141.71% in Q4 2024, compared to 17476.92% in Q3 2024 and 7106.55% in Q2 2024.